LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

243.77 -0.93

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

242.02

Max

247.99

Schlüsselkennzahlen
By Trading Economics
Einkommen	41M 79M
Verkäufe	1.8M 98M
KGV Branchendurchschnitt	35.09 77.671
Gewinnspanne	81.15
Angestellte	275
EBITDA	10M 50M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	-10.14% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.3B 6.8B
Vorheriger Eröffnungskurs	244.7
Vorheriger Schlusskurs	243.77

Nachrichtenstimmung

By Acuity

50%

167 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

133.221 / 169.73 Unterstützung & Widerstand

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Dez. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12. Dez. 2025, 23:49 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. Dez. 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. Dez. 2025, 22:32 UTC

Ergebnisse

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 20:45 UTC

Ergebnisse

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. Dez. 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. Dez. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. Dez. 2025, 19:23 UTC

Ergebnisse

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. Dez. 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. Dez. 2025, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. Dez. 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. Dez. 2025, 17:49 UTC

Ergebnisse

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. Dez. 2025, 17:34 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12. Dez. 2025, 17:33 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12. Dez. 2025, 17:33 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12. Dez. 2025, 17:32 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12. Dez. 2025, 17:31 UTC

Akquisitionen, Fusionen, Übernahmen

Orange to Buy the Stake for EU4.25B in Cash

12. Dez. 2025, 17:24 UTC

Market Talk

Argentina Predicts Record Wheat Crop -- Market Talk

12. Dez. 2025, 17:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 17:18 UTC

Market Talk

Ergebnisse

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12. Dez. 2025, 17:09 UTC

Market Talk

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12. Dez. 2025, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Dez. 2025, 16:47 UTC

Market Talk

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12. Dez. 2025, 16:39 UTC

Market Talk

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12. Dez. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12. Dez. 2025, 16:15 UTC

Ergebnisse

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12. Dez. 2025, 15:35 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 14:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

-10.14% Nachteil

12-Monats-Prognose

Durchschnitt 221.75 USD -10.14%

Hoch 255 USD

Tief 198 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Stimmung

By Acuity

167 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.